Cigna Stock Earnings Reports

Cigna reported a strong Q1 2026: total revenues of $68.5 billion and adjusted EPS of $7.79, prompting management to raise full-year adjusted EPS guidance to at least $30.35. Leadership transition is planned for July 1 with Brian Evanko succeeding David Cordani as CEO and Cordani becoming Executive Chair. Operational highlights: Evernorth (specialty and care services) showed strong volume and specialty drug momentum (including biosimilar adoption) while Pharmacy Benefit Services (PBS) was in line with expectations but down year-over-year due to large client renewals and investments to transition to a new rebate-free PBM model called “Signature.” Cigna Healthcare outperformed expectations with favorable MCR (79.8%) helped by lower flu and weather-related deferrals and higher share of bronze exchange enrollees in Q1. Management announced portfolio actions: exiting the individual ACA exchange business at year-end and initiating a strategic review of eviCore given industry standardization of prior authorization. Management emphasized heavy investment in data, advanced analytics and AI to personalize care, improve affordability, drive biosimilar conversions, identify high-cost claimants earlier, and reduce inbound calls through digital adoption. Capital and cash: operating cash flow was $1.1 billion in Q1, debt-to-capital at 42.3% and expected to improve; capital deployment priorities remain reinvestment, disciplined M&A, dividends and buybacks. Investor Day planned for September.